CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

"Nordic Cold Chain launches cold chain packaging for GLP-1 drugs" was originally created and published by Packaging Gateway, ...

Changes in eating habits are impacting some categories, like snacks, more than others. Taking GLP-1 drugs reduces a person's appetite significantly, slowing down the emptying of the stomach and making ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

Here’s a roundup of numbers from the last week of HR news — including the percentage of managers who use AI to help determine ...

This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...